An anti-CCR8 nanobody and its application
By screening high-affinity anti-CCR8 nanobodies using alpaca nanobody technology, the problems of low efficiency and unverified safety in traditional antibody development have been solved. This approach enables highly specific targeting of CCR8⁺Treg cells in the tumor microenvironment, and has the potential for both therapeutic and diagnostic applications.
Patent Information
- Application Number
- CN202611422320.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-09-14
- Publication Date
- 2026-11-17
AI Technical Summary
Existing technologies suffer from low efficiency, high cost, and unverified safety when targeting CCR8⁺Treg cells in the tumor microenvironment. Traditional antibody development relies on animal immunization and it is difficult to obtain antibodies with high affinity.
Using alpaca nanobody technology, high-affinity anti-CCR8 nanobodies were screened from a natural library. Phage display technology was used for liquid-phase and cell panning to construct a recombinant expression vector and express it in CHO-K1 cells to obtain nanobodies with high affinity and small molecular weight.
The obtained nanobody can recognize human CCR8 protein with high specificity and has an EC50 value of 2.524 nM. It has a small molecular weight, good stability and strong tissue penetration, and is suitable for tumor immunotherapy and diagnosis, supporting precision medicine.
Smart Images

Figure CN123106905A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of molecular biology technology, specifically relating to an anti-CCR8 nanobody and its application. Technical Background
[0002] CCR8 is an important target that has attracted attention in the field of tumor immunotherapy in recent years. Studies have shown that this receptor is relatively highly expressed on regulatory T cells (Tregs) in the tumor microenvironment, while its expression level is low or almost non-existent in most normal tissues and peripheral blood Tregs. This expression pattern makes it a potential target for tumor-specific immunotherapy.
[0003] Recent studies have further confirmed that CCR8 is significantly overexpressed in tumor-infiltrating regulatory T cells (Tregs) of various human solid tumors (including breast cancer, non-small cell lung cancer, colorectal cancer, pancreatic cancer, liver cancer, and head and neck cancer) (Plitas G et al. Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer. Immunity. 2016 Nov 15;45(5):1122-1134. doi:10.1016 / j.immuni.2016.10.032, and DeSimone M et al. Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells. Immunity. 2016 Nov 15;45(5):1135-1147. doi:10.1016 / j.immuni.2016.10.021.). Functional studies have shown that CCR8⁺Tregs in the tumor microenvironment significantly inhibit the proliferation of effector T cells compared to the CCR8⁻Treg subset. Furthermore, the binding of CCR8 to its major ligand CCL1 activates the CCR8 signaling pathway, promoting Treg chemotaxis towards the tumor site and further enhancing their immunosuppressive function, thus assisting the tumor in constructing an immune escape microenvironment. Therefore, targeted clearance of CCR8⁺Tregs is considered a promising new strategy for overcoming tumor immune resistance.
[0004] Based on the above mechanisms, strategies targeting CCR8 are mainly divided into two categories: (1) antagonistic antibodies or small molecule inhibitors, which block signaling pathways to inhibit Treg migration and function; and (2) scavenging antibodies, which selectively eliminate intratumoral CCR8⁺Tregs through antibody-dependent cytotoxicity (ADCC) and other effects. Preclinical animal model studies have confirmed that anti-CCR8 antibodies can not only specifically eliminate intratumoral Tregs and inhibit tumor growth, but also produce synergistic antitumor effects with PD-1 / PD-L1 blockers (VanDamme H et al., J Immunother Cancer, 2021; US20190071508A1). The above evidence collectively indicates that high-affinity anti-CCR8 antibodies have clear potential as monotherapy or combination therapy for CCR8-positive tumors.
[0005] In drug development, nanobody technology provides a unique tool for targeting the complex target CCR8. Nanobodies are currently the smallest known antigen-binding antibody molecules, with a molecular weight of approximately 15 kDa. Compared to traditional antibodies, nanobodies offer advantages such as small relative molecular mass, high affinity, high stability, good solubility, low immunogenicity, strong penetration, simple humanization, and the ability to be expressed in large quantities in *E. coli*. These advantages make them particularly suitable for targeting the dense tumor microenvironment, potentially enabling more precise and efficient intervention against intratumoral CCR8⁺ Tregs. Therefore, the development of high-affinity anti-human CCR8 nanobodies using phage display technology shows promising application prospects.
[0006] Besides its therapeutic applications, CCR8 also has significant diagnostic value. The level of CCR8⁺Treg infiltration in tumor tissue can serve as a prognostic biomarker, and its specific expression also makes it a potential molecular imaging probe for non-invasive tumor detection and dynamic monitoring of treatment efficacy.
[0007] Overall, CCR8 targeted therapy represents a new strategy for intervening in the tumor immune microenvironment, but its safety and efficacy still need to be verified through clinical studies. Summary of the Invention
[0008] The purpose of this invention is to provide an anti-CCR8 nanobody capable of specifically recognizing the CCR8 protein. It also provides the encoding gene, recombinant expression vector, host cell, and related applications of this antibody. This invention develops an anti-CCR8 nanobody using a natural library of alpaca nanobodies, eliminating the need for animal immunization. This approach offers advantages such as low development cost and freedom from antigen immunogenicity limitations. The resulting anti-CCR8 nanobody exhibits high affinity and possesses characteristics such as small molecular weight and strong tissue penetration. It holds promise for effectively targeting CCR8⁺ regulatory T cells (Tregs) in the tumor microenvironment, providing a powerful tool for developing novel tumor immunodiagnostic or therapeutic approaches.
[0009] The technical solution adopted in this invention is:
[0010] In a first aspect of the present invention, an anti-CCR8 nanobody is provided, the nanobody comprising a heavy chain variable region, the heavy chain variable region comprising complementarity-determining regions CDR1, CDR2, and CDR3, wherein: the amino acid sequence of CDR1 is shown in SEQ ID NO:1, the amino acid sequence of CDR2 is shown in SEQ ID NO:2, and the amino acid sequence of CDR3 is shown in SEQ ID NO:3.
[0011] Furthermore, the amino acid sequence of the variable region of the heavy chain of the anti-CCR8 nanobody is as shown in SEQ ID NO:4, or has at least 85%, 88%, 90%, 92% or 95% sequence identity with SEQ ID NO:4.
[0012] In a second aspect of the invention, a nucleic acid encoding an anti-CCR8 nanobody as described in the first aspect is provided.
[0013] In a third aspect of the invention, a recombinant expression vector is provided, the recombinant expression vector comprising the nucleic acid described in the second aspect. In one specific embodiment, the recombinant expression vector is constructed based on the mammalian expression vector pcDNA3.4.
[0014] In a fourth aspect of the invention, a host cell is provided, the host cell containing the recombinant expression vector described in the third aspect.
[0015] Preferably, the host cell is a mammalian cell, more preferably a CHO-K1 cell.
[0016] In a fifth aspect of the invention, an antibody derivative is provided, the antibody derivative comprising the CDR1, CDR2 and CDR3 amino acid sequences shown in the nanobody of the first aspect.
[0017] Antibody derivatives are selected from any one or a combination of the following forms:
[0018] (1) Frame-based variants: humanized antibodies, chimeric antibodies, or variants of their frame regions that have undergone reversion mutations;
[0019] (2) Variants based on valence and specificity: monovalent antibody, multivalent antibody, bispecific antibody or multispecific antibody;
[0020] (3) Fusion proteins based on effector function: fusion proteins fused with human immunoglobulin Fc fragment, fusion proteins fused with human serum albumin binding domain, or fusion proteins fused with cytokines;
[0021] (4) Chemically modified conjugates: polyethylene glycol-modified antibodies, antibody-drug conjugates, antibody-radioactive nuclide conjugates, or antibody-enzyme conjugates;
[0022] (5) Structure-based fragments: antigen-binding fragments of the antibody, or minimal binding peptides containing only the CDR3 sequence.
[0023] In a sixth aspect of the invention, a pharmaceutical composition is provided comprising the anti-CCR8 nanobody described in the first aspect, or the antibody derivative described in the fifth aspect, and a pharmaceutically acceptable carrier.
[0024] In a seventh aspect of the invention, a kit for detecting CCR8 protein is provided, the kit comprising the anti-CCR8 nanobody described in the first aspect, or the antibody derivative described in the fifth aspect.
[0025] In an eighth aspect of the invention, the use of the anti-CCR8 nanobody as described in the first aspect, or the antibody derivative as described in the fifth aspect, in the preparation of reagents or kits for detecting tumors with high CCR8 expression is provided.
[0026] Furthermore, the tumors with high CCR8 expression are selected from: head and neck cancer, breast cancer, pancreatic cancer, colorectal cancer, liver cancer, and non-small cell lung cancer.
[0027] Compared with the prior art, the present invention has the following technical effects:
[0028] This invention obtains anti-CCR8 nanobodies by screening from a natural alpaca nanobody library without the need for animal immunization, avoiding the dependence of traditional immunization methods on antigen immunogenicity or toxicity, significantly reducing antigen usage and development costs, shortening the research and development cycle, and effectively overcoming the problem of antibody screening failure caused by the difficulty in immunizing with antigens, thereby improving the efficiency of obtaining highly specific nanobodies.
[0029] The anti-CCR8 nanobody obtained by this invention can specifically recognize and bind to human CCR8 protein with high affinity, and its EC 50 With a molecular weight of 2.524 nM, this nanobody reaches the sub-nanomolar level. It possesses the typical advantages of nanobodies, such as small molecular weight, good stability, and strong tissue penetration, which facilitates effective contact with target cells in complex physiological environments. Functionally, this nanobody can specifically target regulatory T cells (Tregs) that highly express CCR8 in the tumor microenvironment, and is expected to alleviate local immunosuppression by mediating the clearance or functional inhibition of Tregs, thereby enhancing the anti-tumor immune response.
[0030] The nanobody of the present invention has both therapeutic and diagnostic application potential: on the one hand, it can be used to develop tumor immunotherapy drugs targeting CCR8; on the other hand, it can be applied to the preparation of diagnostic kits, such as detecting the expression level of CCR8⁺ Treg in tumor tissue or peripheral blood by flow cytometry or immunohistochemistry, to assist in clinical assessment of whether patients are suitable for CCR8-targeted therapy and support the implementation of precision medicine strategies. Attached Figure Description
[0031] Figure 1 The results are shown in Example 1. A represents the results of the first round of screening for monoclonal antibodies, and B represents the results of the second round of screening for monoclonal antibodies.
[0032] Figure 2 The results are the sequencing statistics of positive clones in Example 1.
[0033] Figure 3 This is a map of the antibody-mammal system expression vector in Example 2.
[0034] Figure 4 The image shows the SDS-PAGE of the purified antibody from Example 2, where R represents the reduction condition, NR represents the non-reduction condition, and M represents the marker.
[0035] Figure 5 The image shows the binding curve of the purified antibody in Example 2 to the HEK293 hCCR8 overexpressing cell line. Detailed Implementation
[0036] The present invention will be further described in detail below with reference to the embodiments. However, the present invention is not limited to the examples given. Unless otherwise specified, all methods used are conventional methods, and all reagents and materials used are commercially available unless otherwise specified.
[0037] Example 1: Screening anti-CCR8 nanobodies from a natural library of alpaca nanobodies
[0038] Anti-CCR8 nanobodies were screened from a natural library of alpaca nanobodies using phage display technology. A combination of liquid-phase panning and cell panning methods was employed.
[0039] 1. First, perform two rounds of liquid phase panning:
[0040] 1.1 Take three 30 μL aliquots of Dynabeads™ M-280 streptavidin magnetic beads (ThermoFisherScientific, 11206D), wash with 0.05% PBST, add 5% NON-fat Powdered Milk (Sangon Biotech, A600669-0250), block at 25 °C for 1 hour, discard the supernatant to obtain blank magnetic beads; take another phage with 2E+12C.FU, add 5% NON-fat Powdered Milk, block at 25 °C for 1 hour to obtain blocked phage; incubate the blocked phage with three 30 μL aliquots of blank magnetic beads for 0.5 hours each to remove background interference, and collect the supernatant.
[0041] 1.2 Take another 250 μL of Dynabeads™ M-280 streptavidin magnetic beads, add PBS and 15 μg of biotin-labeled hCCR8 / His recombinant protein (Biointron, 9P9XM1001), incubate at 25°C for 1 hour, wash with 0.05% PBST, add 5% NON-fat Powdered Milk, and block at 25°C for 1 hour.
[0042] 1.3 Add the background-removed phage supernatant obtained in step 1.1 to 250 μL of blocked magnetic beads in step 1.2 and incubate at 25°C for 1 hour; remove the phage supernatant that has not bound to the magnetic beads, wash the remaining magnetic beads with 0.05% PBST, resuspend them and add them to the logarithmic phase bacterial culture of TG1 for amplification, and use the obtained phage for the next round of panning.
[0043] 2. Next, two rounds of cell selection are performed:
[0044] 2.1 Take 2E7 HEK293 Blank cells (Biointron) and 1E7 HEK293 hCCR8 cells (Biointron) with a viability of not less than 95% and the cells must be handled on ice throughout the selection process. Resuspend them in 5% BSA-PBS and incubate them at 4°C for 1 hour to block the cells.
[0045] 2.2 Take another 2E+12 CFU of phage, add 5% NON-fat Powdered Milk (Sangon Biotech, A600669-0250), and block at 4°C for 1 hour.
[0046] 2.3 Centrifuge the blocked HEK293 Blank cells at 4℃ for 5 min, discard the supernatant, add the blocked phage from step 2.2, and incubate at 4℃ for 0.5 h for reverse panning (negative sieving), and collect the supernatant.
[0047] 2.4 After the negative screening is completed, the blocked HEK293 hCCR8 cells and the negative-screened phage mixture are centrifuged at 500g and 4℃ for 5min, respectively, and the supernatant is discarded.
[0048] 2.5 Resuspend the HEK293 hCCR8 cells (after desupernatant removal in step 2.4) in the supernatant obtained in step 2.3, incubate at 4°C with rotation for 0.5 h, and perform forward panning. After completion, centrifuge and add the supernatant to the logarithmic phase TG1 bacterial culture for amplification, which will be used for the next round of panning.
[0049] 3. After four rounds of pressure screening, 188 single clones were selected from two plates (94 single clones per plate; one plate was selected from LPR2CP1R1 in the third round and one plate from LP1R2CP1R2 in the fourth round) for single clone screening. The sample preparation process is as follows: 600 μL of 2×YT carbenicillin-containing medium was added to a 96-well deep-well plate, and single clones were inoculated. The plates were incubated at 220 rpm and 37℃ for 3 h. 100 μL of bacterial culture was aspirated from each well and transferred to a new 96-well plate for storage. Then, 100 μL of 2×YT carbenicillin-containing medium and IPTG were added to the original 96-well plate, and expression was induced overnight at 30℃. The following day, the bacterial cells were collected by centrifugation, and the supernatant was discarded. The bacterial cells were lysed with TES buffer (30 mM Tris-HCl, 0.5 M sucrose, 0.5 mM EDTA, pH= 8.0) to release the test fusion protein in the periplasmic space. The resulting periplasmic extract sample was used to bind with hCCR8 positive cells, and its binding activity was detected by flow cytometry to screen positive monoclonals.
[0050] The detection procedure for single clones is as follows: HEK293 hCCR8 and HEK293 GFP cells were mixed 1:1 and then seeded at 1.5E+5 cells / well onto a 96-well V plate. After centrifugation, the supernatant was discarded. Prepared periplasmic extract sample was added at 100 μL / well, mixed by pipetting, and incubated at 4°C for 0.5 hours. After centrifugation, the supernatant was discarded. MACS buffer was added at 200 μL / well, mixed by pipetting, centrifuged, and the supernatant was discarded. The mixture was washed twice. Rabbit anti-M13 mAb [iFlour647] (Critical Point Biology, 052-201-009) was added at 100 μL / well, diluted 1:2000, and incubated at 4°C for 0.5 hours. The control antibody secondary antibody was GoatAnti-hIgG (Fcγ Specific) pAb [Alexa Fluor 647] (Jackson, 109-605-190), 100 μL / well, diluted 1:800, incubated at 4°C for 0.5 hours, centrifuged and the supernatant discarded; MACS buffer, 200 μL / well, was added, mixed by pipetting, centrifuged again and the supernatant discarded, washed twice. Flow cytometry was used to detect the readings. Clones with 3×blank (HEK293hCCR8) < Median < 3×blank (HEK293 GFP) were defined as positive clones. The detection results are as follows: Figure 1 As shown.
[0051] The results showed that 17 out of 188 single clones were positive clones recognizing CCR8. Sequencing analysis of these 17 positive clones yielded 4 unique sequences, with Unique 4 being a dominant enriched clone (e.g., ...). Figure 2 (As shown).
[0052] The dominant monoclonal clone corresponding to Unique4 is ANb-17-CCR8-LP1R2CP1R2-D3, whose amino acid sequence of CDR1 is SEQ ID NO:1, CDR2 is SEQ ID NO:2, CDR3 is SEQ ID NO:3, and the amino acid sequence of the variable region of the nanobody heavy chain is SEQ ID NO:4.
[0053] Example 2: Expression and purification of anti-CCR8 nanobodies in a mammalian system
[0054] The mammalian system expression vector pcDNA3.4 for constructing the ANb-17-CCR8-LP1R2CP1R2-D3 nanobody in Example 1 is shown in the figure. Figure 3Then, plasmids were prepared using this plasmid. CHO-K1 cells were selected as the host cells for antibody expression, with an expression volume of 40 mL. The supernatant after expression was purified using a Protein A affinity chromatography column to obtain high-purity expressed antibodies. Purity was measured by SDS-PAGE, and the results are as follows: Figure 4 As shown, the antibody purity reached 85%.
[0055] Example 3: Detection of the binding ability of the antibody from Example 2 to the HEK293 hCCR8 overexpressing cell line.
[0056] HEK293 hCCR8 and KEK293 Blank cells were mixed 1:1 and the density was 3E+06 cells / mL. In a 96-well V-plate, 50 μL / well of cell suspension (1.50E+5 cells / well) and 50 μL of serially diluted ANb-17-CCR8-LP1R2CP1R2-D3 antibody (starting concentration 100 nM, 3-fold serial dilution) were added to each well and incubated at 4°C for 1 h. After washing twice with MACS buffer, Alexa Fluor® 647 AffiniPure Goat Anti-Human IgG, Fcγ fragment-specific (Jackson Immuno, 109-605-190) was added at a dilution of 1:800 and incubated at 4°C for 0.5 h. After washing twice with MACS buffer, the cells were centrifuged, resuspended in 100 μL of MACS buffer, and analyzed by flow cytometry. FACS binding curves were generated, and the results are shown below. Figure 5 As shown, ANb-17-CCR8-LP1R2CP1R2-D3 has binding activity with the HEK293 hCCR8 overexpressing cell line, with an EC50 value of 2.524 nM.
[0057] Finally, it should be noted that the above embodiments are only illustrative of the principles, performance, and effects of the present invention, and are not intended to limit the present invention. Those skilled in the art can modify or alter the above embodiments without departing from the spirit and scope of the present invention. Therefore, any equivalent modifications or changes based on the spirit and technical ideas disclosed in this invention should be included within the scope of the claims of this invention.
Claims
1. An anti-CCR8 nanobody, characterized in that, The nanobody includes a heavy chain variable region, which contains complementarity-determining regions CDR1, CDR2, and CDR3, wherein the amino acid sequence of CDR1 is shown in SEQ ID NO:1, the amino acid sequence of CDR2 is shown in SEQ ID NO:2, and the amino acid sequence of CDR3 is shown in SEQ ID NO:
3.
2. The anti-CCR8 nanobody as described in claim 1, characterized in that, The amino acid sequence of the variable region of the heavy chain of the anti-CCR8 nanobody is shown in SEQ ID NO:4, or has at least 85%, 88%, 90%, 92% or 95% sequence identity with SEQ ID NO:
4.
3. Nucleic acid encoding the anti-CCR8 nanobody as described in claim 1 or 2.
4. A recombinant expression vector, characterized in that, The recombinant expression vector comprises the nucleic acid described in claim 3.
5. A host cell, characterized in that, The host cell contains the recombinant expression vector as described in claim 4.
6. An antibody derivative, characterized in that, The antibody derivative comprises the CDR1, CDR2, and CDR3 amino acid sequences shown in the anti-CCR8 nanobody of claim 1.
7. The antibody derivative as described in claim 6, characterized in that, The antibody derivative is selected from any one or a combination of the following forms: (1) Frame-based variants: humanized antibodies, chimeric antibodies, or variants of their frame regions that have undergone reversion mutations; (2) Variants based on valence and specificity: monovalent antibody, multivalent antibody, bispecific antibody or multispecific antibody; (3) Fusion proteins based on effector function: fusion proteins fused with human immunoglobulin Fc fragment, fusion proteins fused with human serum albumin binding domain, or fusion proteins fused with cytokines; (4) Chemically modified conjugates: polyethylene glycol-modified antibodies, antibody-drug conjugates, antibody-radioactive nuclide conjugates, or antibody-enzyme conjugates; (5) Structure-based fragments: antigen-binding fragments of the antibody, or minimal binding peptides containing only the CDR3 sequence.
8. A pharmaceutical composition, characterized in that, The pharmaceutical composition comprises the anti-CCR8 nanobody of claim 1 or 2, or the antibody derivative of claim 6, and a pharmaceutically acceptable carrier.
9. A kit for detecting CCR8 protein, characterized in that, The kit contains the anti-CCR8 nanobody as described in claim 1 or 2, or the antibody derivative as described in claim 6.
10. Use of the anti-CCR8 nanobody according to claim 1 or 2 in the preparation of reagents or kits for detecting tumors with high CCR8 expression; wherein the tumors with high CCR8 expression are selected from: head and neck cancer, breast cancer, pancreatic cancer, colorectal cancer, liver cancer, and non-small cell lung cancer.
Citation Information
Patent Citations
Pharmaceutical composition for cancer treatment
US20190071508A1
